A Decade of Therapeutic Challenges in Synchronous Gynecological Cancers from the Bucharest Oncological Institute

Abstract

The aim of our study is to present the particularities of a specific subset of gynecological cancer patients in Romania. We present a review of synchronous gynecological neoplasia (SGN) treated in the Bucharest Oncological Institute’s surgery departments over a decade. Between 2012 and 2022, 7419 female patients with genital malignancies were treated. We identified 36 patients with invasive synchronous primary gynecological cancers (0.5%) and 12 cases with one primary gynecological and another primary invasive pelvic cancer (rectal/bladder). All recurrent, metastatic, or metachronous tumors detected were excluded. Demographic data, personal history, presenting symptoms, pathologic findings, staging, treatment, and evolution for each case were recorded. Usually, the most common SGN association is between ovarian and endometrial cancer of endometrioid differentiation (low-grade malignancies with very good prognosis). However, we noticed that, given the particularities of the Romanian medical system, the most frequent association is between cervical and endometrial, followed by cervical and ovarian cancers. Moreover, the cancer stage at diagnosis is more advanced. In countries with low HPV vaccination rate and low adherence to screening programs, SGNs can present as extremely advanced cases and require extensive surgery (such as pelvic exenterations) to achieve radicality. This multimodal treatment in advanced cases with high tumor burden determines a reduction in survival, time until progression, and quality of life.

A case report of two synchronous primary urologic malignancies in one patient

“…Contrary to the index case, most renal urothelial carcinomas typically present with pre-existing urinary bladder cancer [ 8 ]. Synchronous urologic malignancies often pose diagnostic and treatment challenges [ 9 , 10 ]. Multi-disciplinary tumor board discussion by specialized physicians is essential to maximize treatment outcomes.…”

Breast Reconstruction following Mastectomy for Breast Cancer or Prophylactic Mastectomy: Therapeutic Options and Results

“…However, mortality has been steadily declining for over 30 years, with an average 5-year survival of 86% and 75% at 10 years [7]. This trend is attributed both to the increase in the effectiveness of oncological treatments and to early screenings and screening programs similar to those for other neoplastic diseases [8,9].…”

Why Is Surgery Still Done after Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer in Romania?

“…While there is no formal definition for the term "locally advanced cervical cancer," there is a broad consensus that includes stages IB2 (AJCC 2017)/IB3 (FIGO 2018)-4A [5]. These stages are considered to carry an increased risk of local recurrence and/or metastasis [6] and thus require more aggressive treatment [7].…”